Real-pe study demonstrates statistically significant lower major bleeding rates with the ekos™ endovascular system compared to mechanical thrombectomy device for treatment of pulmonary embolism

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices marlborough, mass. , oct. 24, 2023 /prnewswire/ -- data from the real-pe study was presented today at transcatheter cardiovascular therapeutics (tct), the annual scientific symposium of the cardiovascular research foundation, demonstrating that patients treated for pulmonary embolism (pe) with the boston scientific (nyse: bsx) ekos™ endovascular system (ekos) had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the inari flowtriever® system.
BSX Ratings Summary
BSX Quant Ranking